TNGX vs. OUST, CMPO, DCGO, QSI, PRCH, ARWR, FOLD, MOR, IDYA, and DYN
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include Ouster (OUST), CompoSecure (CMPO), DocGo (DCGO), Quantum-Si (QSI), Porch Group (PRCH), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), MorphoSys (MOR), IDEAYA Biosciences (IDYA), and Dyne Therapeutics (DYN).
Ouster (NYSE:OUST) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Ouster presently has a consensus target price of $12.10, indicating a potential upside of 3.42%. Tango Therapeutics has a consensus target price of $14.17, indicating a potential upside of 104.72%. Given Ouster's stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Ouster.
Tango Therapeutics has lower revenue, but higher earnings than Ouster. Tango Therapeutics is trading at a lower price-to-earnings ratio than Ouster, indicating that it is currently the more affordable of the two stocks.
Ouster has a net margin of -239.89% compared to Ouster's net margin of -299.88%. Ouster's return on equity of -44.35% beat Tango Therapeutics' return on equity.
Ouster has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
In the previous week, Tango Therapeutics had 8 more articles in the media than Ouster. MarketBeat recorded 17 mentions for Tango Therapeutics and 9 mentions for Ouster. Ouster's average media sentiment score of 0.28 beat Tango Therapeutics' score of 0.21 indicating that Tango Therapeutics is being referred to more favorably in the news media.
31.5% of Ouster shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 7.8% of Ouster shares are owned by insiders. Comparatively, 6.2% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ouster received 9 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 63.41% of users gave Ouster an outperform vote while only 62.96% of users gave Tango Therapeutics an outperform vote.
Summary
Tango Therapeutics beats Ouster on 11 of the 18 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
